Emergent BioSolutions (EBS) Amortization - Intangibles (2018 - 2026)

Emergent BioSolutions' Amortization - Intangibles history runs 9 years deep, the most recent figure standing at $16.5 million for Q1 2026.

• On a quarterly basis, Amortization - Intangibles rose 1.23% year-over-year to $16.5 million in Q1 2026; TTM through Mar 2026 was $65.3 million, a 0.15% change from a year earlier, with the FY2025 full-year figure at $65.1 million, changed 0.0% from the prior year.
• Amortization - Intangibles advanced to $16.5 million in Q1 2026 per EBS's latest filing, from $16.3 million in the prior quarter.
• Across five years, Amortization - Intangibles topped out at $17.9 million in Q4 2022 and bottomed at $14.0 million in Q1 2022.
• The 5-year median for Amortization - Intangibles is $16.3 million (2023), against an average of $16.0 million.
• Across the five-year window, Amortization - Intangibles grew 27.86% in 2022 and fell 9.5% in 2023, its largest moves.
• Year by year, Amortization - Intangibles stood at $17.9 million in 2022, then declined by 9.5% to $16.2 million in 2023, then rose by 0.62% to $16.3 million in 2024, then dropped by 0.0% to $16.3 million in 2025, then advanced by 1.23% to $16.5 million in 2026.
• Per Business Quant, the three latest EBS Amortization - Intangibles figures stand at $16.5 million (Q1 2026), $16.3 million (Q4 2025), and $16.3 million (Q3 2025).